title: Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicenter study.
abstract: Six Medical Centers in France were involved in a prospective study evaluating the efficacy of [131I]metaiodobenzylguanidine (131I-MIBG) in the treatment of malignant pheochromocytoma. Fifteen patients aged from 28 to 75 years bearing tumor sites demonstrating a good MIBG uptake were included in this study. Catecholamines were elevated in 13/14 cases, VMA in 9/14 and metanephrines in 13/14. Two to 11 therapeutic activities of 131I-MIBG were administered, with a mean number of therapeutic doses per patient of 4 and a mean single activity of 4.7 GBq (range 2.9 to 9.25 GBq). Seven patients were alive, and seven patients died 6 to 29 months after their first MIBG administration (mean follow-up of 36 months); 1 patient was lost to follow-up. Two patients had a partial tumor response only, 4 had a hormonal response only, and 3 had both a partial tumor response and a hormonal response (complete in 2 cases). Six patients did not respond to the treatment, 4 of them died. Of the 9 responding patients, 4 relapsed, 3 of whom died subsequently. Haematological toxicity was always transient and mild, except in 1 case.
authors.affiliation: University Hospital, Nantes, France.
authors.forename: M
authors.initials: M
authors.lastname: Krempf
authors.forename: J
authors.initials: J
authors.lastname: Lumbroso
authors.forename: R
authors.initials: R
authors.lastname: Mornex
authors.forename: A J
authors.initials: AJ
authors.lastname: Brendel
authors.forename: J L
authors.initials: JL
authors.lastname: Wemeau
authors.forename: M J
authors.initials: MJ
authors.lastname: Delisle
authors.forename: B
authors.initials: B
authors.lastname: Aubert
authors.forename: P
authors.initials: P
authors.lastname: Carpentier
authors.forename: M C
authors.initials: MC
authors.lastname: Fleury-Goyon
authors.forename: C
authors.initials: C
authors.lastname: Gibold
mesh_terms: D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000453:epidemiology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010673:Pheochromocytoma / Q000453:epidemiology / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine